<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531709</url>
  </required_header>
  <id_info>
    <org_study_id>CTMS 20-0061</org_study_id>
    <secondary_id>HSC20200462E</secondary_id>
    <nct_id>NCT04531709</nct_id>
  </id_info>
  <brief_title>Financial Toxicity and Quality of Life in Patients With TGCT</brief_title>
  <official_title>Financial Toxicity and Quality of Life in Patients With Testicular Germ Cell Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cross-sectional, observational study employing validated questionnaires to&#xD;
      investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As&#xD;
      background, TGCTs are the most common malignancies among men from age 15-35. Treatment is&#xD;
      highly curative, but often consists of intensive multi-cycle chemotherapy with significant&#xD;
      potential for physical toxicity. The treatment course itself is disruptive and long term&#xD;
      physical and mental health consequences can increase risk for financial toxicity. Thus, we&#xD;
      aim to study financial toxicity in both patients with TGCT actively receiving treatment and&#xD;
      in TGCT survivors. There will be two separate cohorts: Cohort 1 will consist of subjects with&#xD;
      recently diagnosed TGCT who will undergo multi-agent, multi-cycle chemotherapy and Cohort 2&#xD;
      will consist of subjects who have completed chemotherapy and are long-term survivors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients undergoing treatment for newly diagnosed GCT and GCT patients who are currently in surveillance whose levels of financial toxicity are high.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and type of financial risk factors impacting low levels of health-related quality of life for patients with GCT.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Testicular Neoplasm</condition>
  <arm_group>
    <arm_group_label>Recently diagnosed TGCT</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Long-term survivors of TGCT</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comprehensive Score for financial toxicity (COST)</intervention_name>
    <description>Measure indirect and direct health care cost that burden patients and their loved ones.</description>
    <arm_group_label>Long-term survivors of TGCT</arm_group_label>
    <arm_group_label>Recently diagnosed TGCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functional Assessment of Cancer Therapy: General (FACT-G)</intervention_name>
    <description>General quality of life instrument</description>
    <arm_group_label>Long-term survivors of TGCT</arm_group_label>
    <arm_group_label>Recently diagnosed TGCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EORTC QLQ C-30</intervention_name>
    <description>Assess quality of life in cancer patients</description>
    <arm_group_label>Long-term survivors of TGCT</arm_group_label>
    <arm_group_label>Recently diagnosed TGCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EORTC QLQ-TC26.</intervention_name>
    <description>To measure disease and treatment related quality of life issues relevant to testicular cancer patients that were not explored in the QLQ-C30 questionnaire.</description>
    <arm_group_label>Long-term survivors of TGCT</arm_group_label>
    <arm_group_label>Recently diagnosed TGCT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with testicular germ cell tumors TGCT, divided into non-seminomatous&#xD;
        germ cell tumors (NSGCT) and seminomas; both of which are treated with a combination of&#xD;
        surgery and chemotherapy or radiation depending on stage of disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recently diagnosed TGCT&#xD;
&#xD;
               -  Patients with histologically or clinically confirmed germ cell tumor.&#xD;
&#xD;
               -  Age &gt; 18 years of age.&#xD;
&#xD;
               -  Anticipated treatment with multicycle (&gt; 2 cycles) / multiagent chemotherapy&#xD;
&#xD;
               -  Within 4 weeks of starting C1D1 chemotherapy&#xD;
&#xD;
               -  Signed informed consent&#xD;
&#xD;
          -  Long-term survivors&#xD;
&#xD;
               -  Age &gt; 18 years of age&#xD;
&#xD;
               -  Patients with histologically or clinically confirmed germ cell tumor.&#xD;
&#xD;
               -  Completed treatment for germ cell tumor with multicycle (&gt; 2 cycles) / multiagent&#xD;
                  chemotherapy.&#xD;
&#xD;
               -  Within years 1-5 of surveillance since Day 1 of last cycle of chemotherapy&#xD;
&#xD;
               -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recently diagnosed TGCT&#xD;
&#xD;
               -  Patients planned to receive &lt;2 cycles of chemotherapy&#xD;
&#xD;
               -  Starting chemotherapy greater than 4 weeks after signing consent and completing&#xD;
                  initial survey.&#xD;
&#xD;
               -  Starting chemotherapy prior to consenting and completing initial survey.&#xD;
&#xD;
          -  Long-term survivors&#xD;
&#xD;
               -  Patients undergoing active chemotherapy&#xD;
&#xD;
               -  Patients who did not complete 1st line chemotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mays Cancer Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <phone>210-450-5798</phone>
      <email>goodwine@uthscsa.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>de Souza JA, Yap BJ, Wroblewski K, Blinder V, Ara√∫jo FS, Hlubocky FJ, Nicholas LH, O'Connor JM, Brockstein B, Ratain MJ, Daugherty CK, Cella D. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017 Feb 1;123(3):476-484. doi: 10.1002/cncr.30369. Epub 2016 Oct 7.</citation>
    <PMID>27716900</PMID>
  </reference>
  <results_reference>
    <citation>Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener S. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2015 May;33(5):623-31. doi: 10.1007/s00345-014-1361-y. Epub 2014 Jul 17.</citation>
    <PMID>25030752</PMID>
  </results_reference>
  <results_reference>
    <citation>Baird DC, Meyers GJ, Hu JS. Testicular Cancer: Diagnosis and Treatment. Am Fam Physician. 2018 Feb 15;97(4):261-268. Review.</citation>
    <PMID>29671528</PMID>
  </results_reference>
  <results_reference>
    <citation>Palumbo C, Mistretta FA, Mazzone E, Knipper S, Tian Z, Perrotte P, Antonelli A, Montorsi F, Shariat SF, Saad F, Simeone C, Briganti A, Lattouf JB, Karakiewicz PI. Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors. Clin Genitourin Cancer. 2019 Oct;17(5):e1026-e1035. doi: 10.1016/j.clgc.2019.06.003. Epub 2019 Jun 13.</citation>
    <PMID>31378580</PMID>
  </results_reference>
  <results_reference>
    <citation>Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011 Jan 19;103(2):117-28. doi: 10.1093/jnci/djq495. Epub 2011 Jan 12. Erratum in: J Natl Cancer Inst. 2011 Apr 20;103(8):699.</citation>
    <PMID>21228314</PMID>
  </results_reference>
  <results_reference>
    <citation>Sztankay M, Aaronson NK, Arraras JI, Basso U, Bumbasirevic U, Efficace F, Giesinger JM, Johnson CD, van Leeuwen M, Oberguggenberger AS, Sosnowski R, Young T, Holzner B; European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG). International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26. BMC Cancer. 2018 Nov 12;18(1):1104. doi: 10.1186/s12885-018-5036-8.</citation>
    <PMID>30419889</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

